

EPA's ToxCast™ Program for Predicting Hazard and Prioritizing Toxicity Testing of Environmental Chemicals

Richard Judson
December 13, 2007

judson.richard@epa.gov



This work was reviewed by EPA and approved for presentation but does not necessarily reflect official Agency policy

Outline

- EPA ToxCast Program
 - Developing new approaches to screening and prioritization of environmental chemicals
 - Addresses toxicity data gap
 - Reduces animal use
 - Anticipates NRC report on Toxicity Testing of the 21st Century
- ACToR – Aggregated Computational Toxicology Resource
 - Collecting all the world's publicly available *in vitro* and *in vivo* data on environmental chemicals
 - Includes deep yet-to-be-released toxicology data from EPA

ACToR and ToxCast


Addressing the Toxicity Data Gap

Complete toxicity package includes:


- Acute*
- Subchronic
- Chronic / Cancer
- Developmental *
- Reproductive *
- Immunotox
- Neurotox
- Genotox *
- Dermal
- Respiratory
- Nephrotox
- Endocrine
- Cardiotox
- Hepatotox
- Ecotox*

“Pesticide Food Use Actives” require all - \$Ms/chemical

The World of Environmental Chemicals




Current Data Coverage / Data Gaps for Widely-used Environmental Chemicals




<10% have data for most tests

ACToR is the one-stop shop for this data


Toxicity Prediction Today





Toxicity Prediction Tomorrow: Find Pattern that Predicts Toxicity using Inexpensive Assays




Toxicity Prediction Tomorrow: Find Pattern of Assays that Predicts Tox



Toxicity Prediction Tomorrow: Find Pattern of Assays that Predicts Tox



Toxicity Prediction Tomorrow: Find Pattern of Assays that Predicts Tox




ToxCast Background

- Research program developed by EPA's National Center for Computational Toxicology
- Formulated to address chemical screening and prioritization needs
- Based on experience of the pharmaceutical industry
- Comprehensive use of current technology
- Phased approach to evaluate utility
- Committed to stakeholder involvement and release of data to public domain

Phased Development of ToxCast Program

Phase	Number of Chemicals	Chemical Criteria	Purpose	Number of Assays	Cost per Chemical	Target Date
I	>300	Data Rich (pesticides)	Signature Development	>400	\$20k	FY07-08
II	>1000	Expanded Structure and Use Diversity	Evaluation and Extension	>300	\$15-20k	FY08-09
III	Thousands	Data poor	Prediction and Prioritization	>300	\$10-15k	FY10-12



- Delivers an affordable, science-based system for categorizing chemicals
- Increasing confidence as database grows
- Identify potential mechanisms of action
- Refine and reduce use of animals in hazard identification and risk assessment

Chemical Classes Investigated in ToxCast Phase I

291 pesticide actives with complete toxicity datasets

- 30 Carbamates (plus one metabolite)
- 33 Organophosphates (plus several metabolites)
- 12 Pyrethroids
- 12 Triazines (plus one metabolite)
- 17 Azole Fungicides (plus one metabolite)
- 13 Organochlorines
- 7 Phthalates (and several metabolites)
- 14 HPVs, 11 HPV challenge

56 of 73 chemicals proposed for Tier 1 EDSP

ToxRefDB

Reference In Vivo Toxicology Database

- Office of Pesticide Programs - Data Evaluation Records (DER)
 - 20 years of key primary toxicology data for industry submitted toxicology studies
 - Complete data package for >300 chemicals
 - High quality data with significant QC
 - Incorporate into relational model with expert-developed controlled vocabularies
 - Integrate other primary toxicology sources (NTP, OPPT, European agencies)

First effort to capture, tabulate and mine this unique resource

STUDY TYPE: Combined chronic toxicity/oncogenicity feeding – Rat
OPPTS 870.4300 [§83-5]

DP BARCODE: D257223
P.C. CODE: 111901

SUBMISSION CODE: S564270
TOX. CHEM. NO.: 497AB

TEST MATERIAL (PURITY): Imazalil (purity, 97.4%)

CITATION: Van Deun, K. 1999. Combined oral chronic toxicity/carcinogenicity study with Imazalil in the SPF Wistar rat. Dept. Toxicology, Jans Foundation, 2340 Beerse, Belgium. Laboratory report number, 3817, June 8, 1999. MRID 44858001. Unpublished.

EXECUTIVE SUMMARY:

In a chronic toxicity/oncogenicity study (MRID 44858001), Imazalil (97.4% a.i.) was administered in the diet to groups of 50 male and 50 female F₁ substrain (SPF) Wistar-derived rats at concentrations of 0, 50, 200, 1200, or 2400 ppm (equivalent to 0.0, 2.7, 10.8, 65.8, and 134.8 mg/kg/day for males and 3.6, 14.6, 85.2, and 168.8 mg/kg/day for females) for two years. All rats were observed daily for clinical signs of toxicity and morbidity, weighed and food consumption monitored biweekly. Blood and urine samples were collected after 6, 12, and 18 months of treatment and at study end. Surviving rats were sacrificed after 104 weeks of treatment. All rats were necropsied and the tissues and organs inspected grossly and microscopically for toxicity-related effects. The carcinogenic potential of Imazalil.

Male and female rats in the 1200 ppm and 2400 ppm groups had slightly increased RBCs and slightly decreased MCVs and MCHs that reached significance at most measurement intervals. The differences, however, were within 6% of controls and the historical control limits for rats of this species. No significant treatment-related effects of biological relevance were found for most clinical chemistry parameters. However, plasma triglyceride activities of ALKP, AST, and ALT of male rats in the 2400 ppm group and female rats in the 1200 and 2400 ppm groups were often statistically different and remained within historical control limits. The effects were considered related to malnutrition.

The effect of treatment on the liver (males and females) and thyroid (males only) were confirmed microscopically, but had distinct sex-related etiology. The incidence of clear cell and basophilic foci was equivocal while eosinophilic foci were significantly increased for male rats in the 2400 ppm group. In the 2400 ppm group, the incidences of clear cell and basophilic foci were significantly decreased but the incidence of eosinophilic foci was unaffected. The incidence of hepatocyte fatty vacuolation was increased only in male rats of the 1200 ppm and 2400 ppm groups while the incidence of pigmentation increased only in females of the 200, 1200, and 2400 ppm groups. In addition, the location of hepatocellular hypertrophy was distinctly different. The 1200 and 2400 ppm groups had significant increases in centriacinar and periportal hypertrophy while male rats only had centriacinar hypertrophy. The incidence of thyroid follicular cell hyperplasia was increased only in male rats of the 1200 and 2400 ppm groups.

The lowest observed adverse effect level (LOAEL) for male and female rats was 1200 ppm (65.8 and 85.2 mg/kg/day, respectively) with corresponding no observed adverse effect level (NOAEL) of 200 ppm (10.8 mg/kg/day males, 14.6 mg/kg/day females). These are based on body weight, weight gain, and the macro- and microscopic effects noted in the liver of all rats and the thyroid of male rats.

Male rats had a significant increase in the incidence of hepatocellular adenomas and thyroid follicular neoplasia while no increase was found for females. These results indicate a difference in the disposition of Imazalil between the sexes increases hepatic and thyroid neoplasia in male rats, likely through metabolic activation of the test material.

ToxRefDB Data Entry Status

ToxCast Chemicals

320

Unique Chemicals

308

Pesticide Actives

291

LEGEND

Total ToxCast Unique Chemicals (307)

of Chemicals with Data Coverage

of Chemicals with Complete Data Entry

Studies

1842

1577

988

Study Type

Current as of November 1, 2007

231

207

267

67

263

70

271

149

278

253

267

242

15

Rodent
Subchronic

Rat Devel

Rabbit Devel


Rat MultiGen

Rat Chronic/
Cancer

Mouse Cancer

High-Throughput Screening Assays

*batch testing of chemicals for pharmacological/toxicological endpoints
using automated liquid handling, detectors, and data acquisition*



Human Relevance/
Cost/Complexity

Throughput/
Simplicity



ToxCast HTS Assays



Nine contracts and one IAG providing chemical procurement, biochemical assays, cellular reporter assays and genomics, complex human cell responses, and model organisms; capacity to screen up to 10,000 chemicals in over 400 assays by 2012



Biochemical and Cellular High Throughput Screening (HTS)

Number of Assays

30 Cytochrome P450s

81 GPCRs

22 Ion Channels

28 Kinases

24 Nuclear Receptors

19 Phosphatases

9 Transporters


27 Other Enzymes





Transcription Factor Activity Profiling


Cis-Factorial™ Biosensors




43 transcription factors

attagene

The Home of TFomics™



Trans-Factorial™ Biosensors




24 nuclear receptors

Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries

James Inglese*, Douglas S. Auld, Ajit Jadhav, Ronald L. Johnson, Anton Simeonov, Adam Yasgar, Wei Zheng, and Christopher P. Austin

NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3370

Communicated by Francis S. Collins, National Institutes of Health, Bethesda, MD, May 31, 2006 (received for review April 12, 2006)



PNAS August 2006 vol 103 no 31 11473-11478


Reporter gene assays

From Invitrogen:

- AR
- ERa
- FXR
- GR
- LXRb
- PPARd
- PPARg
- RXR
- TRb
- VDR
- RORa

Considering from other sources:

- PPARa
- PPARb/d
- PPARg
- PXR
- CAR
- FXR
- RXRa
- ERRa
- TRa
- PR
- ERa
- ERb
- AR
- GR
- MR
- LXRa
- LXRb
- VDR
- RORa



Gene Expression Profiling by Microarray and PCR

Human BeadChips assay up to 48,000 transcripts.
Mouse BeadChips assay up to 47,000 transcripts.
RatRef BeadChips assay up to 22,000 transcripts.
Customized chips- up to 1400 genes in 96well format.
Individual or multiplexed PCR (≤ 48 transcripts in parallel).







Toxicogenomic Profiling of Hepatocyte – Kupffer Cell Co-Cultures

- Testing human, mouse and rat
- Coordinating with Virtual Liver project
- Optimized ratio of Hepatocyte – Kupffer cells
- Concentration response
- Focusing analysis on Nuclear Receptor mediated gene expression pathways



Table 1. Endpoints contained within Phase I signature development

Assay Type	Number of Assays	Number of Unique Endpoints	Assay Source	Comment	Source	Reference
Biochemical	+200	+200	Mostly human and rat	Enzyme inhibition, Ion channels, GPCRs, Cytochromes	NovaScreen Biosciences	www.novascreen.com
Transcription Factor Profiling	2	+60	HepG2 cells (human liver)	Nuclear receptors and other transcription factors	Attagene	US Patent Application 20060160108 Populations of reporter sequences and methods of their use; www.attagene.com
Nuclear receptor activation	+20	+20	Human and rodent	Reporter gene assay over 15 concentrations	NIH Chemical Genomics Center	Inglese et al 2006. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 103:11473-8; www.ncgc.nih.gov
Transcriptomics	1	+20,000	Primary hepatocytes-Kupffer cell co-cultures	Illumina microarrays	In Vitro ADMET Laboratories and Expression Analysis	Shi et al 2006. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006 Sep;24(9):1151-61; www.expressionanalysis.com
Kinetic Cell Growth	1	Kinetic	A549 cells (human lung)	Real time recording of electrical impedance	ACEA Biosciences	Xing et al 2006. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro 20:995-1004; www.aceabio.com
Cytotoxicity and Bioactivation	1	6	Primary human liver, lung and kidney cells	Shared metabolism across cell types	In Vitro ADMET Laboratories	Li AP 2007. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 168:16-29; www.invitroadmet.com
Complex cell culture	8	87	Primary human cells	Many cell signaling pathways	Bioseek	Berg et al 2006. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J Pharmacol Toxicol Methods 53:67-74; www.bioseekinc.com
High content screening	1	11	HepG2 cells (human liver)	Fluorescence imaging of cells	Cellumen	Giuliano et al 2006. Systems cell biology based on high-content screening. Methods Enzymol 414:601-19; www.cellumen.com
Fish development	1	11	Zebrafish (Dana rerio)	Teratogenesis	Phylonix	Parg et al 2007. Neurotoxicity assessment using zebrafish. J Pharmacol Toxicol Methods 55:103-112; www.phylonix.com
TOTAL	>235	>20,395				

- Aggregating the world's chemical structure, bioassay and toxicology data for environmental chemicals
 - >150 sources of data – all public
 - Over 15M chemicals
- Manage all ToxCast Data
- Public release planned by June 2008
- Prototype Intranet: <http://134.67.216.45:22722/servlet/ActorPrototype13>



- Chemical Identity (Name / CAS)
- Chemical Structure
- In vitro & cell-based assay data
- In vivo chemical toxicity data
- Browsing by data source
- Searching by name, CAS, structure



ACToR Assay Types

- PhysicoChemical (logP, MW)
- Biochemical (Ki - ToxCast, PubChem)
- Cellular (Cytotoxicity - ToxCast, PubChem)
- Tissue (Tissue slice assay)
- In vivo toxicology
 - Tabular – primary (NTP, OPPIN)
 - Tabular – secondary (IRIS)
 - Summary calls (Scorecard, CalEPA)
 - Summary report via URL (INCHEM)
- Category (from OPPT, Health Canada)
- Regulation (TSCA, FIFRA)
- Description (IUR Usage Levels)

ATSDR_ToxFaq	ESIS_ORATS	NCI-Open_09-03	SRS_OP_RPT_0798
BIND	ESIS_PBT	NCTRER_DSSTOX	SRS_PBT
BioCyc	EU_EINECS	NIAID	SRS_PCB
CalEPA	EXTOXNET	NMRShiftDB	SRS_RCRA_Appendix_VIII
CambridgeSoft	FDAMDD_DSSTOX	NTP1408	SRS_RCRA_F_Waste
CCL	FlameRetardant_1997	NTPBSI_DSSTOX	SRS_RCRA_U_Waste
CERCLA	GRADN	NTPHTS_DSSTOX	SRS_SARA_110
CERHR	GRADN_Oct07	OECD_HPVC	SRS_SARA_302A
ChEBI	HCPSL_1999	OPPIN_Active	SRS_SDWA_NPDWR
ChemDB	HCPSL_2006	OPPIN_ActiveSupported	SRS_SDWA_NSDWR
ChemIDplus	HealthCanada_DSL	OPPIN_AntiMicrobial	SRS_TSCA_4_Tests
CPDBAS_DSSTOX	HPV	OPPIN_AntiMicrobialFoodUse	SRS_TSCA_6_Unreasonable_Risk
Danish_EPA	HPV101_2007	OPPIN_FoodUseActive	SRS_TSCA_6A_CCCR
DBPCAN_DSSTOX	HPVChallenge	OPPIN_Inert	SRS_TSCA_8A_CAIR
DrugBank	HPVCSI_DSSTOX	PAN	SRS_TSCA_8c_SARS
DTP/NCI	HPVIS_All	PCN	SRS_TSCA_8D_HSDR_a
EAFUS	HPVIS_Robust_Summaries	PDSP	SRS_TSCA_8D_HSDR_c
EDC73	INCHEM_CICAD	RBC	SRS_TSCA_8D_HSDR_d
EPA	INCHEM_EHC	RoC	SRS_TSCA_Inventory
EPA_CARC	INCHEM_IARC	Scorecard	SRS_TSCAInvSyns
EPA_DWC	INERTS	SIDS	SRS_TTO
EPA_DWSHA	IRISTR_DSSTOX	SIDS_V1	ToxCast_1408
EPA_HPVC	ITER_TERA	SRS_CAA_112R	ToxCast_320
EPA_PFS_Conventional	IUR_2002	SRS_CAA112_b_HON	TOXNET_GENETOX
EPA_SRS_NTS	IUR_86_02	SRS_CAS-9CI	TOXNET_Toxicology
EPA_TRI_PBT	KEGG	SRS_ChemIDStd	ToxRefDB
EPA_TSCA	KIDB	SRS_CWA_307A	TRI
EPAFHM_DSSTOX	MHLWJP	SRS_CWA_311	WHO_CPH
EPISUITE	MITI_Japan	SRS_HAP	WHO_DiscontinuedPesticides
ESIS_ESIS	MTDP	SRS_HDDs_HDFs	xPharm
ESIS_LPV	NCGC	SRS_NJ_RTK_HS	ZINC



U.S. Environmental Protection Agency

ACToR: Aggregated Computational Toxicology Resource

Recent Additions | Contact Us Search: ☐ All EPA ☒ This Area Go

You are here: [EPA Home](#) » [ACToR](#) » Data Collection





Data Collection: ToxCast_320

Name: [ToxCast_320](#)
Description: ToxCast Main Phase I chemical set
ID: 205
Source Type: ToxCast List
Number of Substances: 320
Number of Generic Chemicals: 306
Compilation Date: TBD
Compilation Instructions: TBD

• [Hide Chemical Table](#)

Page 1 of 7 : [Next](#)

Select Link to Toggle Table Section: [Thumbnails](#) : [SID](#) : [Source_SID](#) : [GCID](#) : [CASRN](#) : [Name](#) : [Categories](#) : [Phenotypes](#) :

Structure	SCID	GCID	CASRN	Name	Hazard	AcuteTox	SubchronicTox	ChronicTox	Carcinogenicity	GeneTox	DevTox	NeuroTox	DevNeuroTox	ImmunTox	DermalTox	RespiratoryTox	NephroTox	HepatoTox	Endocrine	CardioTox	EcoTox	FoodSafe	ToxOther
	11550	431	94-75-7	2,4-D	8	5	1	6	14	22	7	5	4	3	2			1	2	1	4		
	11551	6372	94-82-6	2,4-DB	4	4	1	4	8	7	6	5	2	2			1				2		
	11552	7673	136-45-8	2,5-Pyridinedicarboxylic acid, dipropyl ester	1	1	1	1	5		2	1											
	11553	1124	90-43-7	2-Phenylphenol	4	2	1	2	9	1	3	2	1		1					1		1	1

Data Source
CPDBAS_DSSTOX
HPVCSI_DSSTOX
IRISTR_DSSTOX
NCTRER_DSSTOX
NTPBSI_DSSTOX
NTPHTS_DSSTOX
ToxCast_320
CERCLA
EDC73
EPA_DWC
EXTOXNET
HPVChallenge
HPV
INCHEM_EHC
INCHEM_EHC
INCHEM_IARC
ITER_TERA
IUR_2002
IUR_86_02



ACToR: Aggregated Computational Toxicology Resource

U.S. Environmental Protection Agency


[Recent Additions](#) | [Contact Us](#)

Search: ☐ All EPA ☒ This Area

Go

You are here: [EPA Home](#) » [ACToR](#) » Generic Chemical

Chemical Summary: Propiconazole



GCID:	6467
CASRN:	60207-90-1
CID:	17172
CCID:	17172
Formula	C15H17Cl2N3O2
MW	342.2204
SMILES	Clc1ccc(c(Cl)c1)C3(Cn2ncnc2)OCC(CCC)O3
INCHI	InChI=1/C15H17Cl2N3O2/c1-2-3-12-7-21-15(22-12,8-20-10-18-9-19-20)13-5-4-11(16)6-14(13)17/h4-6,9-10,12H,2-3,7-8H2,1H3
QC Status	QUEUED

[ACToR Home](#)

[About ACToR](#)

[Data Collections](#)

[Search by Name](#)

[Search By Structure](#)

[Browse Assays](#)

[Downloads](#)

[ToxRefDB](#)

[DSSTox](#)

[ToxMiner](#)

[ToxCast](#)

[Chemical Prioritization](#)

[ToxCast Overlap](#)

[National Center for
Computational
Toxicology](#)

[Links](#)

[Contact Us](#)

[Substances](#) [Show](#)

[Synonyms](#) [Show](#)

[Notes](#) [Hide](#)

SCID	Data Collection	Note
7508	IRISTR_DSSTOX	mixture of stereoisomers
11805	ToxCast_320	mixture of stereoisomers
1403526	EPA_SRS_NTS	ACD/Name-to-Structure Batch v. 8.05

[MESH](#) [Hide](#)

[PubMed via MeSH:](#)

- [propiconazole](#)

[MSDS](#) [Show](#)

[External Search by Name and CASRN](#) [Show](#)

[Assay Data by Assay Category](#)

- [Show PhysicoChemical \(30\)](#)
- [Show Biochemical \(0\)](#)
- [Show Genomics \(0\)](#)
- [Show Cellular \(0\)](#)
- [Show Tissue \(0\)](#)
- [Show Organ \(0\)](#)
- [Show Organism \(0\)](#)
- [Show In vivo toxicology \(tabular primary\) \(0\)](#)

)

Assay Name	Assay Component	Value	Units
IRIS	StudyType	Human Health Exposure Toxicity Review for Risk Assessment	
IRIS	Endpoint	cancer, acute; short-term; sub-chronic; chronic; developmental	
IRIS	Species	rodent; human; dog; rabbit	
IRIS	Oral_RID_Assessed	1	
IRIS	Oral_RID_CriticalEffects	gastric mucosal irritation	
IRIS	Oral_RID_mg_per_kg_day	0.013	mg/kg-bw/day
IRIS	Oral_RID_mmol_per_kg_day	3.8E-5	mmol/kg-bw/day
IRIS	Oral_RID_Notes	NOEL (No observed effect level): 1.25 mg/kg-day	
IRIS	Oral_RID_Confidence	High	
IRIS	Inhalation_RFC_Assessed	0	
IRIS	Inhalation_RFC_CriticalEffects	Not assessed under the IRIS program.	
IRIS	WtOfEvidence_Cancer_Assessed	0	
IRIS	WtOfEvidence_1986GuidelineCategories	Not assessed under the IRIS program.	
IRIS	DrinkingWater_OralSlope_Assessed	0	
IRIS	DrinkingWater_PrecursorEffect_TumorType	Not assessed under the IRIS program.	
IRIS	Inhalation_UnitRisk_Assessed	Not assessed under the IRIS program.	
IRIS	Inhalation_PrecursorEffect_TumorType	Not assessed under the IRIS program.	
IRIS	TotalAssessments	1	
WHO Classifications of Pesticide Hazard	Physical State	L	
WHO Classifications of Pesticide Hazard	Main Use	F	
WHO Classifications of Pesticide Hazard	LD50	1520.0	mg/kg
WHO Classifications of Pesticide Hazard	REMARKS	"JMPR 1988, 2005 "	

Toxicity Testing in the Twenty-first Century: A Vision and a Strategy

Committee on Toxicity Testing and Assessment of Environmental Agents

Board on Environmental Studies and Toxicology

Institute for Laboratory Animal Research

Division on Earth and Life Studies

NATIONAL RESEARCH COUNCIL

OF THE NATIONAL ACADEMIES





FIGURE S-1 The committee's vision for toxicity testing is a process that includes chemical characterization, toxicity testing, and dose-response and extrapolation modeling.



ToxCast / ACToR Collaborators

- ToxCast
 - Commercial Data Contractors
 - NCGC
 - OECD
 - CRADA Partners
 - AgChem, Industrial Chemical & Cosmetic companies
 - Assay providers
- ACToR / ToxRefDB
 - EPA Offices (OPP, OPPT, OW)
 - Environment Canada, RIVM, BfR
 - NTP
- Genomics
 - MAQC Project
- EPA STAR Bioinformatics Centers
 - NJ (UMDNJ / Princeton)
 - University of North Carolina

Summary – ToxCast and ACToR

- Address the toxicity data gap for environmental chemicals
- Address the need for screening and prioritization
- Provide large, high quality *in vivo* and *in vitro* data collections for others to use
- Provide a vehicle for collaborative efforts in analyzing and predicting chemical toxicity
- All data will become public in 2008

The ToxCast Team

